DBV Technologies SA is a clinical-stage biopharmaceutical company that specializes in the development of epicutaneous immunotherapy products. The company’s focus is on the development of Viaskin, an electrostatic patch that offers a convenient, self-administered, and non-invasive immunotherapy to patients. Analysts at StockNews.com have recently given DBV Technologies a “sell” rating, but other analysts have issued reports with a “buy” rating. The average rating for the stock is currently “Hold” with an average price target of $5.38. DBV Technologies’ institutional investors have made changes to their positions in the company, with Braidwell LP and VR Adviser LLC purchasing new positions in the fourth quarter worth approximately $18,525,000 and $29,258,000, respectively. In total, 18.37% of the stock is owned by institutional investors and hedge funds. For the latest news and analysts’ ratings for DBV Technologies and related companies, interested individuals can sign up to receive MarketBeat.com’s FREE daily email newsletter.
DBV Technologies (NASDAQ:DBVT) has been given a “sell” rating by analysts at StockNews.com in a research note issued to investors on Wednesday. This comes after other analysts have also released reports about the company, with Goldman Sachs Group lowering DBV Technologies from a “neutral” rating to a “sell” rating in a report on December 16th, while JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 price target on shares of DBV Technologies on March 3rd.
Despite the negative rating from StockNews.com, DBV Technologies still has an average rating of “Hold” and an average price target of $5.38, with four analysts assigning a buy rating to the stock.
Shares of DBVT opened at $1.59 on Wednesday, with a 12 month low of $1.08 and a 12 month high of $3.43. The stock has a market cap of $299.35 million, a P/E ratio of -2.45, and a beta of 1.23. Its 50 day moving average is $1.45, while its two-hundred day moving average is $1.56.
Institutional investors have recently made changes to their positions in the company, with Braidwell LP purchasing a new position in DBV Technologies worth approximately $18,525,000 during the fourth quarter. VR Adviser LLC also purchased a new position in DBV Technologies during the same period worth approximately $29,258,000. Furthermore, Fairmount Funds Management LLC lifted its position in DBV Technologies by 46.2% during the third quarter and now owns 7,064,964 shares of the company’s stock worth $12,505,000 after buying an additional 2,233,809 shares in the last quarter.
In total, 18.37% of the stock is owned by institutional investors and hedge funds.
DBV Technologies is a French clinical-stage biopharmaceutical company that is focused on the development of treatments for severe food allergies.
DBV Technologies SA is a clinical-stage biopharmaceutical company that specializes in the development of epicutaneous immunotherapy products. The company focuses on the development of Viaskin, an electrostatic patch that offers a convenient, self-administered, and non-invasive immunotherapy to patients. For the latest news and analysts’ ratings for DBV Technologies and related companies, interested individuals can sign up to receive MarketBeat.com’s FREE daily email newsletter.
Don’t miss interesting posts on Famousbio
